Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Link
https://www.nature.com/articles/s41391-022-00640-4.pdf
Reference36 articles.
1. Perrone V, Esposti LD, Giacomini E, Veronesi C, Blini V, Oderda M. Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis. Ther Clin Risk Manag. 2020;16:393–401.
2. Rosario DJ, Davey P, Green J, Greene D, Turner B, Payne H, et al. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. World J Urol. 2016;34:1601–9.
3. Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, et al. Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials. Eur Urol. 2021;79:44–53.
4. Cindolo L, Natoli C, De Nunzio C, De Tursi M, Valeriani M, Giacinti S, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer in chemotherapy-naive patients: an Italian analysis of patients’ satisfaction. Clin Genitourin Cancer. 2017;15:520–5.
5. Tema G, Lombardo R, Voglino O, Sica A, Baldassarri V, Nacchia A, et al. Adverse events related to radium-223 treatment: ‘real-life’ data from the Eudra-Vigilance database. Minerva Urol Nephrol. 2021;73:342–8.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Medications mostly associated with ejaculatory disorders: assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries;Urology;2024-02
2. Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology;Frontiers in Oncology;2024-01-31
3. Adverse events related to alpha-blockers: analysis of real-life data from Eudra-Vigilance;Minerva Urology and Nephrology;2023-08
4. Is EMA warning on quinolones and fluoroquinolones really assessed? An EudraVigilance database analysis;Minerva Urology and Nephrology;2023-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3